Inspire Investing LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, Holdings Channel.com reports. The firm bought 5,808 shares of the biopharmaceutical company’s stock, valued at approximately $236,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in HALO. Canada Pension Plan Investment Board bought a new position in shares of Halozyme Therapeutics in the second quarter worth $52,000. Capula Management Ltd purchased a new position in Halozyme Therapeutics during the second quarter worth about $208,000. CIBC Asset Management Inc increased its stake in Halozyme Therapeutics by 15.1% in the 3rd quarter. CIBC Asset Management Inc now owns 5,789 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 758 shares during the last quarter. Eqis Capital Management Inc. raised its holdings in shares of Halozyme Therapeutics by 16.8% in the 2nd quarter. Eqis Capital Management Inc. now owns 5,631 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 808 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. boosted its position in shares of Halozyme Therapeutics by 30.4% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 6,806 shares of the biopharmaceutical company’s stock valued at $277,000 after acquiring an additional 1,588 shares during the last quarter. 90.56% of the stock is owned by institutional investors.
NASDAQ HALO opened at $35.56 on Friday. The company has a 50-day simple moving average of $36.70 and a two-hundred day simple moving average of $39.60. Halozyme Therapeutics, Inc. has a 12-month low of $31.79 and a 12-month high of $56.40. The firm has a market cap of $5.01 billion, a price-to-earnings ratio of 12.75 and a beta of 1.30. The company has a quick ratio of 8.50, a current ratio of 8.99 and a debt-to-equity ratio of 2.79.
Several brokerages have issued reports on HALO. TheStreet upgraded shares of Halozyme Therapeutics from a “c+” rating to a “b” rating in a research report on Monday, September 20th. upped their target price on shares of Halozyme Therapeutics from $27.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, December 2nd. Zacks Investment Research cut Halozyme Therapeutics from a “hold” rating to a “strong sell” rating and set a $30.00 target price on the stock. in a research note on Thursday. JMP Securities reaffirmed a “buy” rating and set a $54.00 price target on shares of Halozyme Therapeutics in a research note on Friday, December 10th. Finally, Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $60.00 to $58.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $51.25.
In other news, CEO Helen Torley sold 50,000 shares of the company’s stock in a transaction dated Monday, November 8th. The shares were sold at an average price of $39.82, for a total transaction of $1,991,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Connie Matsui sold 32,000 shares of the stock in a transaction dated Friday, November 5th. The stock was sold at an average price of $40.38, for a total transaction of $1,292,160.00. The disclosure for this sale can be found here. Corporate insiders own 2.60% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Featured Article: How Do You Calculate Return on Equity (ROE)?
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.